ChromaDex Reports Preliminary 2017 Results

- February 13th, 2018

ChromaDex (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results. As quoted in the press release: Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of approximately $7.5 million, … Continued

ChromaDex (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results.

As quoted in the press release:

Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of approximately $7.5 million, up 69% compared to $4.5 million from continuing operations in the fourth quarter of 2016. The increase in fourth quarter revenues was driven by growth in sales of TRU NIAGEN®. For the full year 2017, net revenues are expected to be approximately $21.2 million from continuing operations, down 2% compared to $21.7 million in 2016 as the Company shifted to an integrated global, consumer facing nutraceutical company.

Click here to read the full press release.

Leave a Reply

Your email address will not be published. Required fields are marked *